The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
41
Acpru /Id# 261162
Grayslake, Illinois, United States
Maximum Observed Plasma Concentration (Cmax) of ABBV-141
Cmax of ABBV-141 will be assessed.
Time frame: Up to Day 85
Time to Cmax (Tmax) of ABBV-141
Tmax of ABBV-141 will be assessed.
Time frame: Up to Day 85
Area Under the Serum Concentration-time Curve (AUC) of ABBV-141 from time 0 to the time of last measurable concentration (AUCt)
AUCt of ABBV-141 will be determined.
Time frame: Up to Day 85
AUC of ABBV-141 from Time 0 to Infinity (AUCinf)
AUCinf of ABBV-141 will be assessed.
Time frame: Up to Day 85
Terminal Phase Elimination Rate Constant (β) of ABBV-141
Terminal phase elimination rate constant (β) of ABBV-141 will be assessed.
Time frame: Up to Day 85
Terminal Phase Elimination Half-life (t1/2) of ABBV-141
Terminal phase elimination half-life (t1/2) of ABBV-141 will be assessed.
Time frame: Up to Day 85
Dose Normalized Cmax of ABBV-141
Dose normalized Cmax of ABBV-141 will be assessed.
Time frame: Up to Day 85
Dose Normalized AUC of ABBV-141
Dose normalized AUC of ABBV-141 will be assessed.
Time frame: Up to Day 85
Number of Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Injection; SC
Time frame: Baseline to Day 85